← Back to Home

Wainua Late-Stage Trial Setback Reshuffles ATTR-CM Drug Race

A cardiac amyloidosis trial that failed to cross the statistical threshold has dealt a setback to AstraZeneca and Ionis’ expansion plans, while pushing competition in the treatment of a rare but fatal cardiomyopathy back onto the hard ground of clinical evidence.

By SURL BioNews

Drug development for rare diseases often swings between carefully accumulated hope and stark clinical endpoints. Wainua, jointly developed by AstraZeneca and Ionis, had been seen as an important step toward bringing RNA-targeted therapy into transthyretin amyloid cardiomyopathy (ATTR-CM). But the latest Phase 3 trial missed its primary endpoint, cooling both the commercial and medical expectations around this path.

According to multiple media reports citing company statements, Wainua failed to show a statistically significant improvement over placebo in a composite measure of cardiovascular death and recurrent cardiovascular events in the Phase 3 CARDIO-TTRansform study. The study added Wainua on top of standard of care to test whether it could further reduce disease-related cardiac risks.

ATTR-CM is a disease caused by transthyretin protein misfolding and depositing in the myocardium, gradually making the heart stiffer, reducing its pumping capacity, and ultimately leading to heart failure. Wainua is an antisense oligonucleotide therapy designed to lower transthyretin protein production and reduce amyloid deposits at the source. But in indications such as cardiomyopathy, where progression is slow and the disease course is complex, biological logic must still translate into sufficiently clear clinical benefit.

The Times reported that the trial enrolled 1,432 patients across 20 countries and 130 study centers, and compared Wainua with placebo over 140 weeks. The companies said they will continue to analyze the full data and plan to present results at the European Society of Cardiology annual meeting in August. Until the full data are available, what can be confirmed for now is that the primary statistical objective was missed, not that all secondary endpoints or specific subgroups are no longer open to discussion.

The market reaction showed that investors had held considerable expectations for the trial. The Times said AstraZeneca’s market value at one point fell by about GBP 14 billion after the news emerged. Investor's Business Daily reported that AstraZeneca shares fell 5.7%, while Ionis plunged 23.9%. The same report noted that BridgeBio shares rose 15.1%, Pfizer edged higher, and Alnylam and other ATTR-CM-related companies were also being reassessed within the competitive landscape.

This trial setback is not only a problem for one company’s drug candidate. In recent years, ATTR-CM has evolved from an underrecognized rare diagnosis into a commercial battleground at the intersection of cardiovascular medicine and precision medicine. Pfizer already has a solid position, while companies such as BridgeBio and Alnylam are seeking space through different mechanisms and clinical strategies. Had Wainua succeeded, it could have given AstraZeneca and Ionis stronger influence in the cardiomyopathy market. Instead, the result has temporarily eased pressure on both established and emerging competitors.

For patients and clinicians, the result is a reminder that lowering a disease-causing protein does not automatically mean improving long-term cardiovascular outcomes. The real key remains the complete trial data: which patients were enrolled, how severe their disease was at baseline, whether the standard-of-care background affected the results, and whether efficacy signals emerged in specific subgroups. Until more details are released in August, Wainua’s future in ATTR-CM remains in a narrow zone where scientific hypothesis, statistical results, and corporate strategy intersect.

References

  1. The Times
  2. The Guardian
  3. Investor's Business Daily